Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2020-10-15
Target enrollment:
Participant gender:
Summary
This is a non-randomized, multicenter, single-stage phase II study of mifepristone in
patients with advanced or metastatic NSCLC who have failed two or more previous chemotherapy
regimens.
The Investigator plans to enroll 18 evaluable patients in Stage 1, and additionally up to 22
evaluable patients in Stage 2 for a total of 40 evaluable patients. Participants will be
followed for overall survival. Current salvage therapy in advanced NSCLC achieves a median
progression free survival time of 10 weeks and overall survival of 10 months. The
Investigator would like to provide evidence that mifepristone will increase the median
progression-free survival time to 15 weeks and overall survival time of 16 months.